Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
Fulcrum Therapeutics (Nasdaq: FULC) will present at the Leerink Partners Global Healthcare Conference in Miami on Tuesday, March 10, 2025 at 1:00 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Fulcrum Therapeutics (Nasdaq: FULC) will present at the Leerink Partners Global Healthcare Conference in Miami on Tuesday, March 10, 2025 at 1:00 p.m. ET.
The presentation will be webcast and accessible via the company’s Events and Presentations investor web page, with a replay available for at least 30 days after the event.
Details
News Market Reaction – FULC
On Mar 3, the day this news came out, FULC closed 0.77% above the previous close.
Data tracked by StockTitan Argus for the Mar 3 session.
Key Figures
- Conference date
- March 10, 2025
- Leerink Partners Global Healthcare Conference presentation
- Presentation time
- 1:00 p.m. ET
- Scheduled time for conference presentation
- Webcast replay period
- 30 days
- Replay available on company website following presentation
Historical Context
-
Reported positive Phase 1b PIONEER data and 2025 financial results.
-
Detailed positive 12-week results from 20 mg PIONEER cohort in sickle cell.
-
Announced upcoming webcast of 12-week PIONEER 20 mg data presentation.
-
Granted 70,000 inducement options at $10.72 under stock incentive plan.
-
Granted 30,400 options to new employees under Nasdaq Rule 5635(c)(4).
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that company management will present at the Leerink Partners Global Healthcare Conference in Miami, FL on Tuesday, March 10, 2025 at 1:00 p.m. ET.
The webcast of the presentation will be accessible HERE or by visiting the "Events and Presentations" section of Fulcrum Therapeutics’ website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcast will be available on Fulcrum Therapeutics’ website for at least 30 days following the presentation.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of HbF for the treatment of SCD. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on X (@FulcrumTx) and LinkedIn.
Contact:
Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.